Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 420

1.

The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells.

Chakraverty R, Flutter B, Fallah-Arani F, Eom HS, Means T, Andreola G, Schwarte S, Buchli J, Cotter P, Zhao G, Sykes M.

J Immunol. 2008 Nov 15;181(10):6820-8.

4.
7.

Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.

Satake A, Inoue T, Kubo S, Taniguchi Y, Imado T, Fujioka T, Horiuchi M, Xu Y, Ikegame K, Yoshihara S, Kaida K, Tamaki H, Okada M, Okamura H, Ogawa H.

Int J Hematol. 2010 Apr;91(3):485-97. doi: 10.1007/s12185-010-0545-5. Epub 2010 Mar 20.

PMID:
20300982
8.

The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.

Palathumpat V, Dejbakhsh-Jones S, Strober S.

Transplantation. 1995 Aug 27;60(4):355-61.

PMID:
7652765
9.

The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.

Dey B, Yang YG, Preffer F, Shimizu A, Swenson K, Dombkowski D, Sykes M.

Transplantation. 1999 Jul 15;68(1):141-9.

PMID:
10428282
10.

Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia.

Zheng H, Matte-Martone C, Jain D, McNiff J, Shlomchik WD.

J Immunol. 2009 May 15;182(10):5938-48. doi: 10.4049/jimmunol.0802212.

11.

Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR.

Blood. 2001 May 1;97(9):2886-95.

12.

Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment.

Kim J, Park K, Kim HJ, Kim J, Kim HA, Jung D, Kim HJ, Choi HJ, Choi SY, Seo KW, Cho HR, Kwon B.

J Immunol. 2008 Nov 15;181(10):7380-9.

13.

Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody.

Zhang C, Lou J, Li N, Todorov I, Lin CL, Cao YA, Contag CH, Kandeel F, Forman S, Zeng D.

J Immunol. 2007 Jan 15;178(2):838-50.

14.

Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity.

Zhang Y, Joe G, Zhu J, Carroll R, Levine B, Hexner E, June C, Emerson SG.

Blood. 2004 May 15;103(10):3970-8. Epub 2004 Feb 5.

15.

Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.

Drobyski WR, Gendelman M, Vodanovic-Jankovic S, Gorski J.

J Immunol. 2003 Mar 15;170(6):3046-53.

16.

APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.

Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, Giannola D, Emerson SG.

J Immunol. 2002 Dec 15;169(12):7111-8.

18.
19.

Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.

Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Sheng Tan H, Jain D, McNiff J, Shlomchik WD.

Blood. 2008 Feb 15;111(4):2476-84. Epub 2007 Nov 28.

20.

The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.

Gonzalez M, Quezada SA, Blazar BR, Panoskaltsis-Mortari A, Rudensky AY, Noelle RJ.

J Immunol. 2002 Nov 15;169(10):5581-9.

Supplemental Content

Support Center